POSSIBILITIES OF METABOLIC AND FUNCTIONAL DISORDERS CORRECTION IN OSTEOARTHRITIS WITH COMPLEX COMORBIDITY
- PMID: 35522872
POSSIBILITIES OF METABOLIC AND FUNCTIONAL DISORDERS CORRECTION IN OSTEOARTHRITIS WITH COMPLEX COMORBIDITY
Abstract
Objective: The aim: To assess the impact of complex metabolic therapy of primary osteoarthritis and type 2 diabetes mellitus under conditions of comorbidity on the course and progression of these pathologies. Patients with comorbidities of primary osteoarthritis and diabetes mellitus are a special group of patients because the importance of these comorbidities is the additional difficulty in diagnosing and conducting adequate therapy, given the close etiopathogenetic links of these conditions, which leads to poor quality of life, increased costs of diagnosis and treatment, increasing the frequency and duration of hospital stay.
Patients and methods: Materials and methods: We examined 67 patients with primary osteoarthritis in comorbidity with diabetes mellitus. Patients were comparable by clinical, gender criteria, the severity of primary osteoarthritis, and treatment received and were divided into two groups: 1st group (n=32) - patients received treatment for OA and diabetes mellitus in accordance with international recommendations; 2nd group (n=35) - patients received treatment as in group 1 + drug alpha-lipoic acid. Determination of the level of the studied parameters was performed before and after treatment.
Results: Results: The analysis of the obtained results revealed statistically significant positive dynamics after treatment for symptoms of primary osteoarthritis in both study groups of patients (p<0.05), but the therapeutic effect in the 2nd group was more significant (p<0.05). There was a statistically significant positive dynamics on the scale of VAS at rest and movement (p<0,05), WOMAC index for pain, stiffness, and functional insufficiency (p<0,05), and Leken index in the 2nd group after treatment compared with the 1st (p<0.05).
Conclusion: Conclusions: The obtained results indicate a statistically significant positive effect of alpha-lipoic acid on the course and progression of primary osteoarthritis under conditions of comorbidity with diabetes mellitus.
Keywords: diabetes mellitus; exocrine pancreatic insufficiency; family medicine; primary osteoarthritis.
Similar articles
-
Exploring the Efficacy of Alpha-Lipoic Acid in Comorbid Osteoarthritis and Type 2 Diabetes Mellitus.Nutrients. 2024 Oct 2;16(19):3349. doi: 10.3390/nu16193349. Nutrients. 2024. PMID: 39408316 Free PMC article.
-
[Evaluation of therapy efficiency in patients with combined course of copd and osteoarthritis].Wiad Lek. 2016;69(2 Pt 2):214-8. Wiad Lek. 2016. PMID: 27487536 Russian.
-
Additional impact of concomitant hypertension and osteoarthritis on quality of life among patients with type 2 diabetes in primary care in Germany - a cross-sectional survey.Health Qual Life Outcomes. 2009 Feb 27;7:19. doi: 10.1186/1477-7525-7-19. Health Qual Life Outcomes. 2009. PMID: 19250524 Free PMC article.
-
Links between osteoarthritis and diabetes: implications for management from a physical activity perspective.Clin Geriatr Med. 2015 Feb;31(1):67-87, viii. doi: 10.1016/j.cger.2014.08.019. Epub 2014 Oct 7. Clin Geriatr Med. 2015. PMID: 25453302 Free PMC article. Review.
-
The effect on comorbidity and pain in patients with osteoarthritis.J Pain Palliat Care Pharmacother. 2008;22(4):336-48. doi: 10.1080/15360280802536649. J Pain Palliat Care Pharmacother. 2008. PMID: 21923322 Review.
Cited by
-
Exploring the Efficacy of Alpha-Lipoic Acid in Comorbid Osteoarthritis and Type 2 Diabetes Mellitus.Nutrients. 2024 Oct 2;16(19):3349. doi: 10.3390/nu16193349. Nutrients. 2024. PMID: 39408316 Free PMC article.
-
Recent advances in the management of knee osteoarthritis: a narrative review.Front Med (Lausanne). 2025 Jan 21;12:1523027. doi: 10.3389/fmed.2025.1523027. eCollection 2025. Front Med (Lausanne). 2025. PMID: 39906596 Free PMC article. Review.
-
Predictive analysis of osteoarthritis and chronic pancreatitis comorbidity: complications and risk factors.Front Endocrinol (Lausanne). 2024 Nov 6;15:1492741. doi: 10.3389/fendo.2024.1492741. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39568811 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical